|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||1.0900 - 1.0900|
|52 Week Range||1.0100 - 1.9000|
|Beta (5Y Monthly)||-0.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 06, 2019|
|1y Target Est||N/A|
Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian cancer. The agreement will see Sweden-based Oasmia assume exclusive worldwide rights to develop and commercialize Cantrixil for all indications, with an initial focus on ovarian cancer. Oasmia's lead product, Apealea (paclitaxel micellar), is approved in Europe for adult patients with the first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer, and is in late-stage development in the U.S. Oasmia expects to commence a Phase 2 study of Cantrixil in ovarian cancer in 2022. Under the terms of the agreement, Oasmia will make an upfront payment of $4 million to Kazia, with contingent milestone payments of up to $42 million and double-digit royalties on commercial sales. Cantrixil is a proprietary formulation of the potent and selective third-generation benzopyran, TRX-E-002-1, that targets the entire spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells (cancer stem cells) thought to be responsible for disease relapse. In December last year, Kazia announced a Phase 1 study's top-line results and determined the maximum tolerated dose of Cantrixil to be 5 mg/kg. Price Action: KZIA closed 3.9% lower at 9.9 on Friday. See more from BenzingaClick here for options trades from BenzingaAslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic DermatitisMerck's Cough Drug Gefapixant Application Accepted For US Review© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
NEW YORK, NY / ACCESSWIRE / February 19, 2021 / Oasmia Pharmaceutical AB (STO:OASM) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 19, 2021 at 10:00 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
BROOKLYN, N.Y., Feb. 01, 2021 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. and Hagens Berman Sobol Shapiro LLP announces that the United States District Court for the Eastern District of New York has approved the following announcement of the proposed class action settlement that would benefit purchasers of American Depositary Shares of Oasmia Pharmaceuticals AB (OTCMKTS: OASMY): SUMMARY NOTICE OF PENDENCY AND PROPOSED CLASS ACTION SETTLEMENT TO:ALL PERSONS WHO PURCHASED OR OTHERWISE ACQUIRED OASMIA PHARMACEUTICAL AB ADSs FROM OCTOBER 23, 2015 THROUGH OCTOBER 14, 2019, BOTH DATES INCLUSIVE. YOU ARE HEREBY NOTIFIED, pursuant to an Order of the United States District Court for the Eastern District of New York, that a hearing will be held on May 19, 2021, at 11:00 a.m. before the Honorable Nicholas G. Garaufis, United States District Judge of the Eastern District of New York, United States Courthouse, Room 1426 S, 225 Cadman Plaza East, Brooklyn, NY 11201 for the purpose of determining: (1) whether the proposed settlement of the claims in the above-captioned Action (“Settlement”) for consideration including the sum of $2,350,000 (“Settlement Amount”) should be approved by the Court as fair, reasonable, and adequate; (2) whether the proposed plan to distribute the Settlement proceeds is fair, reasonable, and adequate; (3) whether the application of attorneys for Lead Plaintiffs (“Plaintiffs’ Counsel”) for an award of attorneys’ fees of up to one-third plus interest of the Settlement Amount, reimbursement of expenses of not more than $70,000 and an incentive payment of no more than $18,000 in aggregate, or $6,000 each, to Lead Plaintiffs, should be approved; and (4) whether this Action should be dismissed with prejudice as set forth in the Stipulation and Agreement of Settlement dated May 29, 2020 (the “Settlement Stipulation”). The Court may also hold the hearing telephonically or by videoconference. If you purchased Oasmia Pharmaceutical AB (“Oasmia”) publicly-traded American Depository Shares (“ADS”) during the period from October 23, 2015 through October 14, 2019, both dates inclusive (the “Settlement Class Period”), you are a “Settlement Class Member” and your rights may be affected by this Settlement, including the release and extinguishment of claims you may possess relating to your ownership interest in Oasmia securities. If you have not received a detailed Notice of Pendency and Proposed Settlement of Class Action (“Notice”) and a copy of the Proof of Claim and Release Form (“Proof of Claim”), you may obtain copies by writing to or calling the Claims Administrator at: Oasmia Pharmaceutical AB Securities Litigation, c/o Strategic Claims Services, 600 N. Jackson St., Ste. 205, P.O. Box 230, Media, PA 19063; (Tel) (866) 274-4004; (Fax) (610) 565-7985; firstname.lastname@example.org. If you are a Settlement Class Member, in order to share in the distribution of the Net Settlement Fund, you must electronically submit a properly completed Proof of Claim by 11:59 p.m. on April 5, 2021 to the Claims Administrator, establishing that you are entitled to recovery. If you are unable to electronically submit a Proof of Claim, you may mail a Proof of Claim at your own expense. If you are a Settlement Class Member, in order to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim and Release Form postmarked no later than April 5, 2021 to the Claims Administrator, establishing that you are entitled to recovery. Unless you submit a written exclusion request, you will be bound by any judgment rendered in the Action whether or not you make a claim. If you want to be excluded from the Settlement Class, you must submit to the Claims Administrator a request for exclusion so that it is received no later than April 28, 2021, in the manner and form explained in the Notice. All members of the Settlement Class who have not requested exclusion from the Settlement Class will be bound by any judgment entered in the Action pursuant to the Settlement Stipulation. Any objection to the Settlement, Plan of Allocation, or Plaintiffs’ Counsel’s request for an award of attorneys’ fees and reimbursement of expenses and award to Lead Plaintiffs must be in the manner and form explained in the detailed Notice and received no later than April 28, 2021, to each of the following: Clerk of the CourtUnited States District CourtEastern District of New York225 Cadman Plaza EastBrooklyn, NY 11201 LEAD COUNSEL:Jonathan Horne THE ROSEN LAW FIRM, P.A.275 Madison Avenue, 40th Floor New York, NY 10016 COUNSEL FOR DEFENDANTS:Jeff G. HammelLATHAM & WATKINS LLP885 Third Avenue, Suite 1000New York, NY 10022 If you have any questions about the Settlement, you may call or write to Plaintiffs’ Counsel: HAGENS BERMAN SOBOL SHAPIRO LLPDanielle Smith Reed Kathrein715 Hearst Avenue, Suite 202Berkeley, CA email@example.com THE ROSEN LAW FIRM, P.A.Jonathan Horne275 Madison Avenue, 40th Floor New York, New York firstname.lastname@example.org PLEASE DO NOT CONTACT THE COURT OR THE CLERK’S OFFICE REGARDING THIS NOTICE. Dated: January 6, 2021 BY ORDER OF THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF NEW YORK